MDS to sell pharma unit for $50M

Canadian health sciences company MDS Incsaid is selling its late-stage pharma services unit to INC Research for $50 million. The unit--which covers Phase II to IV development--employs 800 workers and conducts trials in more than 25 countries. Report

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.